The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline and somatic MUTYH mutations: Clinicopathologic and mutational analysis in a pan-cancer cohort.
 
Antoine Desilets
Honoraria - Merck Serono; Need
Travel, Accommodations, Expenses - Adlai Nortye; AstraZeneca; Exelixis; Regeneron
 
Matteo Repetto
Travel, Accommodations, Expenses - Sanofi
 
Yelena Kemel
No Relationships to Disclose
 
Aliya Khurram
No Relationships to Disclose
 
Diana Mandelker
No Relationships to Disclose
 
Chaitanya Bandlamudi
No Relationships to Disclose
 
Bryan Novak
Stock and Other Ownership Interests - Mindset Pharma
 
Cristal Velilla
No Relationships to Disclose
 
Pier Selenica
No Relationships to Disclose
 
Allison L. Richards
No Relationships to Disclose
 
Mark Donoghue
No Relationships to Disclose
 
Britta Weigelt
Employment - AstraZeneca (I)
Stock and Other Ownership Interests - Repare Therapeutics (I)
Consulting or Advisory Role - Bain Capital Life Sciences (I); Goldman Sachs (I); PAIGE (I); Repare Therapeutics (I); SAGA Diagnostics (I); Volition RX (I)
Research Funding - Repare Therapeutics
 
Marc Ladanyi
Stock and Other Ownership Interests - PAIGE.AI
Consulting or Advisory Role - ADC Therapeutics; Bayer Health; Bayer Health; MSD
Research Funding - ADC Therapeutics (Inst); Elevation Oncology (Inst); Helsinn Therapeutics (Inst); Merus NV (Inst); Rain Therapeutics
Patents, Royalties, Other Intellectual Property - Royalties from a license agreement between MSK and Sophia Genetics
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Amgen
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Piro Lito
Leadership - BioTheryX; Frontier Medicines
Stock and Other Ownership Interests - Biotheryx; Frontier Medicines
Consulting or Advisory Role - AmMax Bio; BioTheryX; Black Diamond Therapeutics; Frontier Medicines; OrbiMed; PAQ-Tx; Repare Therapeutics; Revolution Medicines
Speakers' Bureau - Boehringer Ingelheim; Ikena Oncology
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Revolution Medicines (Inst); Virtec pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on a patent application filed by MSKCC that describes an approach to treat BRAF mutant cancers. (Inst); I am listed as an inventor on a patent application filed by MSKCC that describes an approach to treat KRAS mutant cancers. (Inst)
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Alexander E. Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Neurogene (I); Novartis (I); Optos (I); Outlook Therapeutics (I); Regeneron (I)
Patents, Royalties, Other Intellectual Property - Intellectual property rights (SOPHiA Genetics) (Inst)
Other Relationship - JCO Precision Oncology, Associate Editor; UpToDate, Section Editor
 
Yonina R. Murciano-Goroff
Employment - Memorial Sloan Kettering Cancer Center (MSK has institutional financial interests relative to Elucida Oncology); Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Research Funding - Abbvie (Inst); Andrew Sabin Family Foundation; Bristol-Myers Squibb (Inst); Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Endeavor Biomedicines